Empagliflozin Good Manufacturer supply High Quality 864070-44-0
- Molecular Formula:C23H27ClO7
- Molecular Weight:450.916
- Boiling Point:665℃
- PKA:13.23±0.70(Predicted)
- Flash Point:356℃
- PSA：108.61000
- Density:1.398
- LogP:1.61340
Empagliflozin (864070-44-0) Usage
Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, was originally discovered by Boehringer Ingelheim and codeveloped and co-marketed through research collaboration with Eli Lilly and Co. It was first approved by European Medicine Agency (EMA) in May 2014, followed by the approval of the US FDA in August 2014. SGLT2 inhibitors are anewclass of glucose-lowering agents developed for the treatment of type 2 diabetes mellitus, which have a mechanism of action that is independent of pancreatic b-cell function or the degree of insulin resistance. Consequently, SGLT2 inhibitors have the potential to be of use not only as standalone therapy but also in combination with any of the existing classes of glucose-lowering agents, including insulin. Empagliflozin selectively inhibits SGLT2, which in turn prevents glucose reabsorption by excreting excess glucose in the urine.
How to get the best price on Empagliflozin?
Zibo Hangyu Biotechnology Development Co., Ltd is a quality supplier and manufacturer of Empagliflozin . You can buy high quality, low price Empagliflozin 864070-44-0 here.
Zibo Hangyu Biotechnology Development Co., Ltd. is a comprehensive chemical enterprise focusing on fine chemical products and pharmaceutical intermediates, integrating research and development, production and sales. The company is equipped with advanced equipment quality inspection and research center. At the same time, the company has excellent talents with rich experience in process development and quality control. To provide customers with total solutions from raw material processing to chemical synthesis systems. The company has established a standardized and perfect quality standard system to provide stable and high quality production and service.
Milestones
- 2012yearThe company was founded, began to engage in the production and supply of chemical raw materials
- 2014yearExpand the scale of production, pharmaceutical raw materials production workshop was established
- 2016yearCooperated with domestic and foreign chemical platforms to promote self-produced and high-end pharmaceutical intermediates
- 2019yearIn recent years to participate in the international pharmaceutical raw materials exhibitions
- 2023yearBusiness continues to expand, Production and Sales teams continue to grow
- 2026yearPlans to set up foreign branches
![6,8-Dichloroimidazo[1,2-b]pyridazine](/upload/2024/6/91c26b78-7ea6-49b3-9244-7333d57bf41e.png)
